Legend Capital sees Mancando's extensive network of brick-and-mortar outlets as the key to bringing greater supply chain efficiency to the Chinese auto parts industry
GIC Private has led a RMB850 million ($125.5 million) Series C round for Burning Rock, a Chinese cancer diagnostics start-up that is already working with hospitals on products based on DNA sequencing analysis.
Sciwind Biosciences, a Chinese drug developer focused on treating metabolic disorders, has raised RMB200 million ($29 million) in Series A funding led by Legend Capital, with participation from existing investors Shiyu Capital and Beijing-based biotech...
EQT has agreed to acquire a minority stake in VBill, a third-party payment services provider in China that focuses on small and medium-sized enterprises (SME) for RMB378 million ($55.8 million).
TuSimple, a China and US-based developer of autonomous driving technology for trucks, has closed its Series D round at $95 million, achieving a pre-money valuation of $1 billion.
Sustainable Bioproducts left stealth mode to raise a $33 million Series A round as it targets commercialization for an edible protein technology that won early backing from NASA
Vision Knight Capital has led a RMB200 million ($29 million) Series C round for Soocas, a Shenzhen-based manufacturer of personal care products such as electric toothbrushes and hairdryers.
C-Bridge Capital has announced a licensing agreement with Samsung Bioepis that is intended to help the Korean biopharmaceutical specialist expand into the China market.
Shanghai-based cancer drug developer HaiHe Biopharma has raised $146.6 million in a funding round led by Chinese private equity firm Huagai Capital.
Mancando, an automotive parts supplier based in Guangdong province, has raised RMB170 million ($25 million) in Series A funding led by Eastern Bell Venture Capital, with participation from Legend Capital.
IDG Capital and Lilly Asia Ventures (LAV) have joined a $10 million investment in EdiGene, a developer of genetics-based therapies based in Beijing.
Maoyan Entertainment, a Chinese online movie ticketing business backed by Tencent Holdings and several private equity investors, fell on its trading debut in Hong Kong following a HK$2.25 billion ($287.1 million) IPO.
Ascendent Capital Partners is seeking $800 million for its third China mid-market fund. The GP closed its previous vehicle at $600 million in 2015.
Investors are looking to capitalize on the China distress opportunity, and recent activity in around non-performing loans suggests there will be enough deal flow to sate their appetites
Redpoint China Ventures secures $400 million for its traditional early-stage investments as well as for an expansion into growth round coverage
China has unveiled details of the highly anticipated new technology and innovation board, which is set to adopt a registration-based system that should allow a shorter route to liquidity for PE and VC investors.
Addressing Chinese demand was central to QIC’s acquisition of cattle breeder North Australian Pastoral, but the company has repositioned itself in response to changing patterns of consumption in global beef markets
Shanghai-based Nasn Automotive, a manufacturer of vehicle wiring and brake systems, has raised RMB400 million ($60 million) in a Series B round of funding led by Matrix Partners China.
Ningbo-based industrial hazardous waste processor Nuoke Huanjing Keji has raised RMB250 million ($37.2 million) in a Series A round of funding participated by US-China Green Fund and Avic Trust.
Chang Guang Satellite Technology, a China-based commercial satellite developer, has raised RMB250 million ($37 million) in angel funding, underlining growing investor interest in space-related technology.
Recent troubles in China’s autonomous driving space highlight the challenges venture capital investors face in picking the right founders to back and then managing those relationships in a productive way
Advent International recognized BioDuro as a company uniquely positioned to leverage growth in pharmaceutical R&D outsourcing in China and the US
The expansion of private equity activity in developing markets is translating into greater due diligence pressure on LPs seeking reliable fund managers. Solutions are intuitive but difficult
China consumer-focused private equity firm ClearVue Partners is seeking to raise $600 million for its third fund. It comes nearly two years after the GP closed Fund II at $362 million.